From TAMIJump to navigationJump to search
Doing cancer research openly, publishing data while searching for effective drugs.
In the post-genomic era, the discovery of cancer genes has become relatively straightforward. Cancer biologists and geneticists now race, like modern cartographers, to assimilate this information as a unified geography of cell signaling pathways. For the cancer patient, these advances allow a detailed, highly individualized understanding of cancer's hard-wiring. Unfortunately, the delay in the discovery and delivery of targeted therapeutics remains a significant concern. We invoke a utilitarian model of drug discovery which is not restricted by any individual chemistry or technology. We support a collaborative, creative approach to drug discovery focused on the most pressing targets irrespective of perceived 'druggability' or profitability. -- Lab research page excerpt.
Not open research specific. To be sorted and moved to specific sections, or separate page.
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- bbc reporting on Riken / _ research published in journal Cell Stem Cell about cancer & HIV attacking T-cells. Not proven to differentiate. Early stage. Reported as promising.
- Teams at the University of Tokyo and the Riken Research Centre for Allergy and Immunology used advances in stem cell technology to make more T-cells.